Pembrolizumab versus Ipilimumab in Advanced Melanoma
Pembrolizumab versus Ipilimumab in Advanced Melanoma
About this item
Full title
Author / Creator
Robert, Caroline , Schachter, Jacob , Long, Georgina V , Arance, Ana , Grob, Jean Jacques , Mortier, Laurent , Daud, Adil , Carlino, Matteo S , McNeil, Catriona , Lotem, Michal , Larkin, James , Lorigan, Paul , Neyns, Bart , Blank, Christian U , Hamid, Omid , Mateus, Christine , Shapira-Frommer, Ronnie , Kosh, Michele , Zhou, Honghong , Ibrahim, Nageatte , Ebbinghaus, Scot , Ribas, Antoni and KEYNOTE-006 investigators
Publisher
United States: Massachusetts Medical Society
Journal title
Language
English
Formats
Publication information
Publisher
United States: Massachusetts Medical Society
Subjects
More information
Scope and Contents
Contents
In a multinational, randomized study, pembrolizumab produced significantly improved progression-free and overall survival and less high-grade toxicity than did ipilimumab in patients with metastatic melanoma.
Two therapeutic strategies have improved survival for patients with advanced melanoma in recent years: immunotherapy with checkpoint inhib...
Alternative Titles
Full title
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Authors, Artists and Contributors
Author / Creator
Schachter, Jacob
Long, Georgina V
Arance, Ana
Grob, Jean Jacques
Mortier, Laurent
Daud, Adil
Carlino, Matteo S
McNeil, Catriona
Lotem, Michal
Larkin, James
Lorigan, Paul
Neyns, Bart
Blank, Christian U
Hamid, Omid
Mateus, Christine
Shapira-Frommer, Ronnie
Kosh, Michele
Zhou, Honghong
Ibrahim, Nageatte
Ebbinghaus, Scot
Ribas, Antoni
KEYNOTE-006 investigators
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_2119956334
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2119956334
Other Identifiers
ISSN
0028-4793
E-ISSN
1533-4406
DOI
10.1056/NEJMoa1503093
